默沙东(MSD)的推出在英国和西班牙SAFLUTAN™(tafluprost),并在其他国家提供更多的发射,预计在未来数月,待监管部门的批准,该公司今天说。 Tafluprost,第一个不含防腐剂眼科前列腺素,被授权在发射市场的升高的眼压与原发性开角型青光眼和高眼压症合适的患者(眼压)减少。 Tafluprost是F2α的前列腺素合成类似物,并可能提供青光眼患者的好处,包括谁的病人患有慢性眼疾或某些不良反应与眼睛眼睛滴含有防腐剂,例如那些谁也干/敏感。 Tafluprost可作为患者谁将会受益于不含防腐剂的眼药水,单药治疗有效反应的第一线治疗,或不能耐受或禁忌到第一线治疗。它可作为辅助治疗,以β-阻断剂。建议剂量是一种tafluprost下降,受影响的似乎(意味着)曾经在晚报。 4月15日,2009年,默克公司,作为该公司默沙东或MSD和参天制药有限公司许多国家开展业务,公司宣布了一项全球许可协议tafluprost。根据协议条款,默克公司同意支付转会费以及里程碑和专利使用费的基础上在未来的销售tafluprost独家商业权利交换(保持和不含防腐剂配方),在西欧(不包括德国tafluprost ),北美,南美和非洲。 Santen公司将保留商业权利tafluprost在东欧,北欧大多数国家和亚太地区国家,包括日本。默克公司将提供促销支持Santen公司在德国和波兰。如果tafluprost是在美国获得批准,Santen公司将拥有共同推动在那里的选择。 SAFLUTAN行销MSD和TAFLOTAN ®,Santen公司在各自领土上销售,是国内唯一不含防腐剂前列腺素可与目前青光眼患者。 Saflutan(tafluprost) 1. NAME OF THE MEDICINAL PRODUCT SAFLUTAN® 15 micrograms/ml eye drops, solution, single-dose container 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM A clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications As monotherapy in patients: o who would benefit from preservative free eye drops o insufficiently responsive to first line therapy o intolerant or contra-indicated to first line therapy. As adjunctive therapy to beta-blockers. 4.2 Posology and method of administration The recommended dose is one drop of SAFLUTAN in the conjunctival sac of the affected eye(s) once daily in the evening. The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use.
No dosage alteration in elderly patients is necessary.
Tafluprost is not recommended for use in children or adolescents below age 18 due to a lack of data on safety and efficacy.
Tafluprost has not been studied in patients with renal/hepatic impairment and should therefore be used with caution in such patients.
To reduce the risk of darkening of the eyelid skin the patients should wipe off any excess solution from the skin. As with any other eye drops, nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route. If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart. 4.3 Contraindications 4.4 Special warnings and precautions for use The change in iris pigmentation occurs slowly and may not be noticeable for several months. The change in eye colour has predominantly been seen in patients with mixed coloured irises, e.g. blue-brown, grey-brown, yellow-brown and green-brown. The risk of lifelong heterochromia between the eyes in unilateral cases is obvious. There is no experience with tafluprost in neovascular, angle-closure, narrow-angle or congenital glaucoma. There is only limited experience with tafluprost in aphakic patients and in pigmentary or pseudoexfoliative glaucoma. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis. There is no experience in patients with severe asthma. Such patients should therefore be treated with caution. 4.5 Interaction with other medicinal products and other forms of interaction In clinical studies tafluprost was used concomitantly with timolol without evidence of interaction. 4.6 Pregnancy and lactation SAFLUTAN must not be used in women of childbearing age/potential unless adequate contraceptive measures are in place (see section 5.3).
There are no adequate data from the use of tafluprost in pregnant women. Tafluprost can have harmful pharmacologic effects on pregnancy and/or the fetus/newborn child. Studies in animals have shown reproductive toxicity (see section 5.3). Therefore, SAFLUTAN should not be used during pregnancy unless clearly necessary (in case no other treatment options are available).
It is unknown whether tafluprost is excreted in human milk. A study in rats has shown excretion of tafluprost in breast milk after topical administration (see section 5.3). Therefore, tafluprost should not be used during breast-feeding. 4.7 Effects on ability to drive and use machines no influence on the ability to drive and use machines. As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
4.8 Undesirable effects The following undesirable effects related to treatment were reported during clinical trials with tafluprost in Europe and the US after a maximum follow-up of 12 months: Within each frequency grouping, adverse reactions are presented in order of decreasing frequency.
Very common (1/10): conjunctival/ocular hyperaemia Common (1/100 to <1/10): eye pruritus, eye irritation, eye pain, changes in eyelashes (increased length, thickness and number of lashes), dry eye, eyelash discolouration, foreign body sensation in eyes, erythema of eye lid, blurred vision, increased lacrimation, blepharal pigmentation, eye discharge, reduced visual acuity, photophobia, eyelid oedema and increased iris pigmentation. Uncommon (1/1000 to <1/100): superficial punctate keratitis (SPK), asthenopia, conjunctival oedema, blepharitis, ocular discomfort, anterior chamber flare, conjunctival follicles, allergic conjunctivitis, anterior chamber cell, conjunctival pigmentation and abnormal sensation in eye.
Common (1/100 to <1/10): headache
Uncommon (1/1000 to <1/100): hypertrichosis of eyelid 4.9 Overdose If overdose occurs, treatment should be symptomatic. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties ATC code: S01EE05
Tafluprost is a fluorinated analogue of prostaglandin F2α. Tafluprost acid, the biologically active metabolite of tafluprost, is a highly potent and selective agonist of the human prostanoid FP receptor. Tafluprost acid has a 12-fold higher affinity for the FP receptor than latanoprost. Pharmacodynamic studies in monkeys indicate that tafluprost reduces intraocular pressure by increasing the uveoscleral outflow of aqueous humour.
Reduction of intraocular pressure starts between 2 and 4 hours after the first administration and maximum effect is reached at around 12 hours after instillation. The duration of effect is maintained for at least 24 hours. Pivotal studies with a tafluprost formulation containing the preservative benzalkonium chloride have demonstrated that tafluprost is effective as monotherapy and has an additive effect when administered as adjunctive therapy to timolol: In a 6-month study, tafluprost showed a significant IOP lowering effect of 6 to 8 mmHg at different time points of the day as compared to 7 to 9 mmHg with latanoprost. In a second 6-month clinical study, tafluprost reduced IOP by 5 to 7 mmHg as compared to 4 to 6 mmHg with timolol. The IOP lowering effect of tafluprost was maintained in the extension of these studies up to 12 months. In a 6-week study, the IOP-lowering effect of tafluprost was compared with its vehicle when used adjunctively with timolol. Compared to baseline values (measured after a 4-week run in on timolol), the additional IOP-lowering effects were 5 to 6 mmHg in the timolol-tafluprost group and 3 to 4 mmHg in the timolol-vehicle group. The preserved and the non-preserved formulations of tafluprost showed a similar IOP-lowering effect of over 5 mmHg in a small cross-over study with a 4-week treatment period.
When rabbits were treated for 4 weeks with a tafluprost 0.0015% ophthalmic solution once daily, the optic nerve head blood flow was significantly increased compared to baseline when measured by the laser speckle flowgraphy on Days 14 and 28. 5.2 Pharmacokinetic properties In a rabbit study, the absorption of tafluprost into the aqueous humour was comparable after a single ocular instillation of unpreserved or preserved tafluprost 0.0015% ophthalmic solution. In monkeys, there was no specific distribution of radiolabelled tafluprost in the iris-ciliary body or choroid including retinal pigment epithelium, which suggested low affinity for melanin pigment. The principle metabolic pathway of tafluprost in humans is the hydrolysis to tafluprost acid and further beta-oxidation to the pharmacologically inactive 1,2-dinor and 1,2,3,4-tetranor tafluprost acids, which may be glucuronated or hydroxylated. Cytochrome P450 (CYP) enzyme system is not involved in the metabolism of tafluprost acid. 5.3 Preclinical safety data Increased contraction of rat and rabbit uteri in vitro was observed at tafluprost acid concentrations that exceeded 4 to 40 times, respectively, the maximum plasma concentrations of tafluprost acid in humans. Uterotonic activity of tafluprost has not been tested in human uterus preparations. Reproduction toxicity studies were performed in the rat and rabbit with intravenous administration. In rats, no adverse effects on fertility or early embryonic development were observed at systemic exposure over 12 000 times the maximum clinical exposure based on Cmax or greater than 75 times based on AUC. In conventional embryo-foetal development studies, tafluprost caused reductions in foetal body weights and increases in post-implantation losses. Tafluprost increased the incidence of skeletal abnormalities in rats as well as the incidence of skull, brain and spine malformations in rabbits. In the rabbit study, plasma levels of tafluprost and its metabolites were below the level of quantification. In a pre- and postnatal development study in rats, increased mortality of newborns, decreased body weights and delayed pinna unfolding were observed in offspring at tafluprost doses greater than 20 times the clinical dose. The experiments in rats with radiolabelled tafluprost showed that around 0.1% of the topically applied dose on eyes was transferred into milk. As the half-life of active metabolite (tafluprost acid) in plasma is very short (not detectable after 30 minutes in humans), most of the radioactivity probably represented metabolites with little, or no pharmacologic activity. Based on metabolism of the drug and natural prostaglandins, the oral bioavailability is expected to be very low. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Sodium dihydrogen phosphate dihydrate Disodium edetate Polysorbate 80 Hydrochloric acid and/or sodium hydroxide for pH adjustment Water for injections. 6.2 Incompatibilities 6.3 Shelf life After first opening a foil pouch: 28 days. 6.4 Special precautions for storage After opening the foil pouch: • Keep the single-dose containers in the original foil pouch • Do not store above 25°C • Discard an opened single-dose container with any remaining solution immediately after use. 6.5 Nature and contents of container The following pack sizes are available: 30 x 0.3 ml single-dose containers and 90 x 0.3 ml single-dose containers. Not all pack sizes may be marketed. 6.6 Special precautions for disposal and other handling 7. MARKETING AUTHORISATION HOLDER Hertford Road Hoddesdon Hertfordshire EN11 9BU, UK |
他氟前列素眼药水|Saflutan(tafluprost)简介:
默沙东(MSD)的推出在英国和西班牙SAFLUTAN™(tafluprost),并在其他国家提供更多的发射,预计在未来数月,待监管部门的批准,该公司今天说。 Tafluprost,第一个不含防腐剂眼科前列腺素,被授 ... 责任编辑:admin |
最新文章更多
推荐文章更多
热点文章更多 |